Idactamab  (Synonyms: INT-001)

Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5)^[1][2].

ASCT2 (SLC1A5)^[1]

Idactamab inhibits different heme cancer cell lines with IC₅₀ of 0.05-65 ng/mL^[1].
ASCT2 (SLC1A5) is a multi-pass, Na⁺-dependent neutral amino acid transporter that mediates the uptake of amino acids required for tumor growth and progression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Idactamab improves 3 disseminated Acute Myeloid Leukemia (AML) cell line models: The survival rates of TF1α (high expression of ASCT2), MOLM-13 (low expression of ASCT2) and M.V.411 (high expression of ASCT2) were 0.05 mg/kg, 0.1 mg/kg, and 0.1 mg/kg, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

2245205-37-0

Liquid

Colorless to light yellow

[Idactamab]

Shipping with dry ice.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071.

  [2]. Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13_Supplement): LB-295-LB-295.